Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Inflammatory Bowel Diseases

  Free Subscription


09.06.2025

1 Aliment Pharmacol Ther
1 Am J Gastroenterol
5 BMC Gastroenterol
1 Clin Gastroenterol Hepatol
1 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
1 Gastroenterol Hepatol
1 Gastroenterology
1 Gut
2 Inflamm Bowel Dis
1 J Clin Gastroenterol
3 J Crohns Colitis
2 Lancet Gastroenterol Hepatol
1 PLoS Comput Biol
3 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. OSOOLI M, Voghera S, Bruze G, Nordenvall C, et al
    Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006-2021.
    Aliment Pharmacol Ther. 2025 Jun 1. doi: 10.1111/apt.70203.
    PubMed         Abstract available


    Am J Gastroenterol

  2. SOLITANO V, Ogunsakin RE, Yuan Y, Bernstein CN, et al
    Effectiveness and Safety of Advanced Combination Treatment (ACT) in patients with refractory inflammatory bowel disease or concomitant immune mediated disease or extra-intestinal manifestations: A Multi-Center Canadian Study.
    Am J Gastroenterol. 2025 Jun 5. doi: 10.14309/ajg.0000000000003573.
    PubMed         Abstract available


    BMC Gastroenterol

  3. LIU H, Shen Y, Xu J, Huang S, et al
    Comprehensive evaluation of clinical phenotypes and pathogenic features in late-onset monogenic inflammatory bowel disease: a comparative study with infantile-onset cases.
    BMC Gastroenterol. 2025;25:432.
    PubMed         Abstract available

  4. JAIN AV, Gopal S, Shetty AJ, Shenoy S, et al
    Predictive accuracy of fecal calprotectin in assessing clinical activity and disease severity in patients with Ulcerative Colitis and Crohn's disease.
    BMC Gastroenterol. 2025;25:429.
    PubMed         Abstract available

  5. ZHANG Z, Du N, Xu CM, Chen W, et al
    Global, regional, and national burden of inflammatory bowel disease in persons aged 60-89 years from 1992 to 2021.
    BMC Gastroenterol. 2025;25:425.
    PubMed         Abstract available

  6. LEE YJ, Kwon EJ, Park DI, Park SH, et al
    Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial.
    BMC Gastroenterol. 2025;25:417.
    PubMed         Abstract available

  7. BULDUKOGLU OC, Ocal S, Akca S, Atar GE, et al
    A novel inflammatory biomarker in assessing disease activity in ulcerative colitis: gasdermin D.
    BMC Gastroenterol. 2025;25:418.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  8. SAMNANI S, Ray CM, Gill P, Stein L, et al
    Diagnostic Accuracy of Non-Invasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2025 Jun 2:S1542-3565(25)00455.
    PubMed         Abstract available


    Dig Dis Sci

  9. CHAEMSUPAPHAN T, Limsrivilai J
    Ustekinumab Dose Optimization in Ulcerative Colitis: Is More Always Better?
    Dig Dis Sci. 2025 May 31. doi: 10.1007/s10620-025-09108.
    PubMed        


    Eur J Gastroenterol Hepatol

  10. SCALVINI D, Bezzio C, Maimaris S, Lenti MV, et al
    A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.
    Eur J Gastroenterol Hepatol. 2025 May 19. doi: 10.1097/MEG.0000000000003005.
    PubMed         Abstract available


    Gastroenterol Hepatol

  11. HERRERO-RODRIGUEZ S, Martin-Cordero L, Mayordomo R, Galvez I, et al
    Sex-based differences in the relationship between health-related quality of life, physical activity, and inflammatory markers in people with Crohn's disease.
    Gastroenterol Hepatol. 2025 May 30:502494. doi: 10.1016/j.gastrohep.2025.502494.
    PubMed         Abstract available


    Gastroenterology

  12. HANZEL J, Solitano V, Vuyyuru SK, Panaccione R, et al
    An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
    Gastroenterology. 2025 May 28:S0016-5085(25)00825.
    PubMed         Abstract available


    Gut

  13. BARNICH N, Arthur JC, Buisson A, Campbell BJ, et al
    Adherent-invasive Escherichia coli in Crohn's disease: the 25th anniversary.
    Gut. 2025 Jun 5:gutjnl-2025-335331. doi: 10.1136/gutjnl-2025-335331.
    PubMed         Abstract available


    Inflamm Bowel Dis

  14. NISHIDA Y, Hosomi S, Fujimoto K, Kobayashi Y, et al
    Lack of Efficacy of Concomitant 5-Aminosalicylic Acid With Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
    Inflamm Bowel Dis. 2025 May 21:izaf088. doi: 10.1093.
    PubMed        

  15. YANOFSKY R, Jogendran R, Hoxha T, Pathak A, et al
    The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: A Systematic Review and Meta-analysis.
    Inflamm Bowel Dis. 2025 Jun 4:izaf095. doi: 10.1093.
    PubMed         Abstract available


    J Clin Gastroenterol

  16. ARIF TB, Ahmad J, Afzal N, Butt MA, et al
    Temporal Trends in Mortality Related to Crohn's Disease in the United States: A 21-year Retrospective Analysis of CDC-WONDER Database.
    J Clin Gastroenterol. 2025 Jun 9. doi: 10.1097/MCG.0000000000002209.
    PubMed         Abstract available


    J Crohns Colitis

  17. BAI J, Bouwknegt DG, Weersma RK, Dijkstra G, et al
    Gene-Environment Interactions in Inflammatory Bowel Disease: A Systematic Review of Human Epidemiologic Studies.
    J Crohns Colitis. 2025;19:jjaf061.
    PubMed         Abstract available

  18. WEWER MD, Lophaven S, Lakatos PL, Gonczi L, et al
    Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study.
    J Crohns Colitis. 2025 Jun 3:jjaf089. doi: 10.1093.
    PubMed         Abstract available

  19. EVERHOV AH, Askling J, Soderling J, Halfvarson J, et al
    Cancer Incidence in Patients with Ulcerative Colitis Naive to or Treated with Thiopurine and Targeted Therapies- a cohort study 2007 to 2022 with comparison to the general population.
    J Crohns Colitis. 2025 Jun 2:jjaf091. doi: 10.1093.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  20. FEAGAN BG, Sands BE, Siegel CA, Dubinsky MC, et al
    Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00071.
    PubMed         Abstract available

  21. LINDSAY J
    Tulisokibart shows promise for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00103.
    PubMed        


    PLoS Comput Biol

  22. GOLDMAN M, Zhao C, Pollard KS
    Improved detection of microbiome-disease associations via population structure-aware generalized linear mixed effects models (microSLAM).
    PLoS Comput Biol. 2025;21:e1012277.
    PubMed         Abstract available


    PLoS One

  23. YUAN J, Gao C, Xin W, Meng F, et al
    Screening and validation of 3'-Methoxydaidzein as a therapeutic agent in ulcerative colitis based on disulfidptosis-associated molecular clusters.
    PLoS One. 2025;20:e0324586.
    PubMed         Abstract available

  24. TEKIN L, Genc D
    CCR2 overexpressing gingiva mesenchymal stem cells provide high intestinal regeneration in a rat model of ulcerative colitis.
    PLoS One. 2025;20:e0325566.
    PubMed         Abstract available

  25. LIU N, Hou Y, Yu M, Liu G, et al
    Identification of novel drug targets through integrative PWAS of brain and plasma proteins with Ulcerative Colitis GWAS.
    PLoS One. 2025;20:e0324035.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.